State Street’s BridgeBio Pharma BBIO Stock Holding History

State Street’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$330M	Sell	4,435,932 -498,388	-10%	-$34.9M	0.01%	760
2026 Q1	$366M	Sell	4,934,320 -28,546	-0.6%	-$2.07M	0.01%	661
2025 Q4	$380M	Sell	4,962,866 -643,474	-11%	-$42.2M	0.01%	645
2025 Q3	$291M	Sell	5,606,340 -290,256	-5%	-$14.2M	0.01%	751
2025 Q2	$255M	Buy	5,896,596 +146,977	+3%	+$5.35M	0.01%	775
2025 Q1	$199M	Sell	5,749,619 -433,008	-7%	-$14.6M	0.01%	895
2024 Q4	$170M	Buy	6,182,627 +219,973	+4%	+$5.68M	0.01%	1036
2024 Q3	$152M	Buy	5,962,654 +108,514	+2%	+$2.85M	0.01%	1088
2024 Q2	$148M	Buy	5,854,140 +461,278	+9%	+$12.6M	0.01%	1043
2024 Q1	$167M	Buy	5,392,862 +305,963	+6%	+$10.4M	0.01%	979
2023 Q4	$205M	Buy	5,086,899 +46,485	+0.9%	+$1.4M	0.01%	826
2023 Q3	$133M	Sell	5,040,414 -2,028,946	-29%	-$57.6M	0.01%	997
2023 Q2	$122M	Buy	7,069,360 +1,926,347	+37%	+$29M	0.01%	1091
2023 Q1	$85.3M	Sell	5,143,013 -3,701,930	-42%	-$43.2M	﹤0.01%	1294
2022 Q4	$67.4M	Buy	8,844,943 +902,132	+11%	+$8.64M	﹤0.01%	1430
2022 Q3	$79M	Sell	7,942,811 -3,014,252	-28%	-$31.3M	0.01%	1276
2022 Q2	$99.5M	Buy	10,957,063 +1,750,829	+19%	+$14.6M	0.01%	1150
2022 Q1	$93.4M	Buy	9,206,234 +5,683,771	+161%	+$58.3M	﹤0.01%	1339
2021 Q4	$58.8M	Buy	3,522,463 +438,604	+14%	+$18.6M	﹤0.01%	1701
2021 Q3	$145M	Buy	3,083,859 +430,363	+16%	+$23.1M	0.01%	1014
2021 Q2	$162M	Buy	2,653,496 +288,124	+12%	+$16.5M	0.01%	970
2021 Q1	$146M	Buy	2,365,372 +68,849	+3%	+$4.5M	0.01%	964
2020 Q4	$163M	Sell	2,296,523 -57,985	-2%	-$2.8M	0.01%	835
2020 Q3	$88.3M	Sell	2,354,508 -831,813	-26%	-$26.2M	0.01%	1047
2020 Q2	$104M	Buy	3,186,321 +1,472,605	+86%	+$44.9M	0.01%	931
2020 Q1	$49.7M	Buy	1,713,716 +905,473	+112%	+$28.1M	﹤0.01%	1253
2019 Q4	$28.3M	Buy	808,243 +456,605	+130%	+$12.7M	﹤0.01%	1897
2019 Q3	$7.55M	Buy	+351,638	New	+$9.73M	﹤0.01%	2598

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

State Street's BBIO Position: Q2 2026 in Review

State Street reduced its BridgeBio Pharma (BBIO) stake by 10% in Q2 2026, selling an estimated $34.9M and leaving 4,435,932 shares worth $330M. The position accounts for 0.01% of the portfolio, ranked #760.

State Street first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. The position peaked at $380M in Q4 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

State Street held 4,435,932 shares of BridgeBio Pharma worth $330M as of Q2 2026.
State Street sold 498,388 BridgeBio Pharma shares in Q2 2026, an estimated $34.9M.
BridgeBio Pharma made up 0.01% of State Street's portfolio in Q2 2026, its #760 holding.
State Street first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
State Street's BridgeBio Pharma position peaked at $380M in Q4 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.